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Abstract 
Association  of  immune  thrombocytopenic
purpura and tuberculosis is a rare condition. In
5  patients  presenting  with  this  association,
anti-tuberculous therapy was effective on both
tuberculosis and thrombocytopenia suggesting
a causal relationship between tuberculosis and
immune thrombocytopenic purpura
Introduction
Immune thrombocytopenic purpura (ITP) is
characterized by a low platelet count associated
with  the  presence  of  platelet  autoantibodies.
The diagnosis of ITP remains a diagnosis of
exclusion,  and  a  bone  marrow  examination
should be performed in patients with atypical
features. In 5-10% of cases, ITP is associated
with  chronic  infection  (HIV,  HCV),  systemic
autoimmune disorders, lymphoproliferative dis-
orders,  and  primary  immunodeficiency.  In
adults, ITP is usually chronic (i.e. more than six
months  in  duration).
1 The  response  to  treat-
ment is defined as an increase in platelet count
above 50ￗ10
9/L, with at least a 2-fold increase in
the initial value and remission is considered if
platelet count reaches 150ￗ10
9/L.
2
We describe 5 cases of the association of
tuberculosis and ITP and the effectiveness of
anti-tuberculous therapy (ATT) on both tuber-
culosis and thrombocytopenia (Figure 1).
Case Reports
Patients were 3 men and 2 women (Table 1).
Median  age  was  38  years.  Major  symptoms
were  pulmonary  symptoms  in  3  cases  and
bleeding in 2 cases. However, thrombocytope-
nia was symptomatic in 4 patients. In 4 of the
5 cases, clinical manifestations of tuberculosis
and  ITP  were  concomitant.  In  one  case
(patient  3),  chest  radiography  abnormalities
were detected four months after the diagnosis
of  thrombocytopenia.  For  each  patient,  ITP
diagnosis was based on a platelet count below
30ￗ10
9/L and normal bone marrow examina-
tion. No patient had splenomegaly. Other sec-
ondary forms of ITP were excluded. All patients
responded to high-dose intravenous immuno  -
globulin  (HD-IVIg)  as  in  most  cases  of  ITP;
2
however,  none  had  complete  and  sustained
response.  In  3  patients,  platelet  counts
remained below 30ￗ10
9/L despite corticosteroid
and  HD-IVIg.  These  patients  had  partial
response  to  danazol  or  vincristine.  Myco  -
bacterium tuberculosis was identified in culture
in 3 patients. Histological examination of an
adenopathy confirmed the diagnosis in the 2
others. Each strain of mycobacterium tuberculo-
sis was  sensitive  to  conventional  therapy.  All
patients completed treatment and were consid-
ered to be cured for tuberculosis. Within two
months  of  anti-tuberculous  therapy,  all  5
patients  were  in  ITP  complete  response  and
were off specific therapy for thrombocytopenia.
Patient  2  required  corticosteroid  for  three
months for associated hemolytic anemia. 
Discussion
ITP may require treatment with oral pred-
nisone or HD-IVIg. Response rates are almost
75%; however, only 20% of adult patients with
ITP achieve persistent remission.
1 In the pres-
ent series, all patients had persistent or refrac-
tory ITP. No patient was cured at the time of
tuberculosis diagnosis or within the month fol-
lowing the onset of ATT. However, within three
months of ATT, ITP was in complete response
in all patients. None required further ITP treat-
ment or splenectomy. 
Persistence of thrombocytopenia during the
first month of ATT may be explained by the fact
that  Mycobacterium  tuberculosis can  remain
alive in the first two months of anti-tubercu-
lous therapy.
3 These results suggest a direct
relationship between tuberculosis and ITP.
ITP is a rare manifestation of tuberculosis.
To our knowledge only 18 reports describing 27
cases of ITP associated with tuberculosis have
been reported.
4-6 All patients were treated with
ATT in combination with corticosteroid, HD-
IVIg or vincristine. In all cases platelet count
recovered with ATT. The correction of thrombo-
cytopenia in all patients within two months of
ATT  suggests  a  causal  relationship  between
tuberculosis and thrombocytopenia, although
the mechanism remains unknown.
Few causatives conditions may bind throm-
bocytopenia to tuberculosis. The presence of
an underlying disease causative of thrombocy-
topenia may favor tuberculosis. HIV infection
is a well known cause of ITP and tuberculosis.
1
Autoimmune  disorders  and  lymphoprolifera-
tive diseases, that may cause ITP, are by them-
selves  or  when  treated,  immunosupressive
conditions.
1 None of our patients had such an
etiology.
Disseminated  tuberculous  infection  may
cause peripheric or central thrombocytopenia.
Tuberculous splenic abcess is rare but a possi-
ble  cause  of  hypersplenism  and  peripheric
thrombocytopenia. None of our patients had
splenomegaly.  All  patients  had  bone  marrow
aspiration  to  confirm  peripheric  thrombocy-
topenia,  while  bone  marrow  involvement  of
tuberculosis may provoke central thrombocy-
topenia. Hemophagocytic lymphohistiocytosis
is  an  uncontrolled  activation  of  T  cells  and
macrophages,  and  an  overproduction  of
inflammatory cytokines responsible for throm-
bocytopenia and anemia. It has been previous-
ly  decribed  secondary  to  tuberculosis.
7
However, bone marrow aspirate excluded this
diagnosis.
Appearance of thrombocytopenia after treat-
ment of tuberculosis is classically induced by
rifampicin  and  recovered  after  stopping
rifampicin.
8 On the contrary, development of
tuberculosis after long-term steroid treatment
is not uncommon while steroids are immuno-
suppresive. One of our patients (case 3) had
received  corticoid  before  the  diagnosis  of
tuberculosis was made. At first she was asymp-
tomatic and chest radiography was considered
as  normal.  But  four  months  later,  she  was
coughing  and  dyspneic;  chest  radiography
revealed abnormalities and Ziehl coloration of
the sputum was positive for BAAR. The short
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course of steroids (less than a month) and the
brief period between steroid treatment and the
discovery  of  radiographic  abnormalities  sug-
gest that active tuberculosis was already pres-
ent when steroids were prescribed and that the
treatment only favored progression of tubercu-
losis. In all other cases, active tuberculosis and
thrombocytopenia were concomitant.
The  pathophysiology  of  thrombopenia  in
tuberculosis  remains  unanswered.  This  is  a
rare condition, estimated to occur in less than
1%  of  cases  of  tuberculosis.  Mycoba-
cter  ium tuberculosis may share antigene with
platelet leading to antiplatelet antibody forma-
tion. Specific HLA presentation of tuberculosis
could  also  lead  to  antiplatelet  immunity
response in some patients.
1 However, only one
patient developed an auto-antibody. In this case,
these  were  anti-hematia  antibodies  revealed
with Coombs testing. None of our patients test-
ed positive for antinuclear antibodies. 
Tuberculosis is a rare but curative cause of
thrombocytopenia. Thrombocytopenic patients,
and particularly chronic and hard to treat ITP,
should benefit from tuberculosis depistage.
In  cases  of  tuberculosis  associated  ITP,
recurrence of thrombocytopenia is frequent in
the first two months, and patients may benefit
from close observation leading to a continua-
tion of ITP specific therapy.
Table 1. Characteristics of the 5 patients with immune thrombocytopenic purpura and tuberculosis.
Patient Age/Sex Delay between  Tuberculosis 
ITP and  Symptoms CT scan Diagnosis Duration of
tuberculosis treatment
1 56/M None Pulmonary Tree in bud pattern Sputum culture 6 months 
bronchiolitis of the 
upper lobes
2 16/F None Asthenia Retroperitoneal  Biopsy of the  9 months
adenopathy adenopathy
3 40/F 4 months Pulmonary Cavernous  Sputum culture 6 months
destruction of the 
left upper lung
4 38/M None Fever Pulmonary  Biopsy of an 6 months
micronodules and  adenopathy
mediastinal adenopathies
5 26/M None Pulmonary Cavernous destruction  Sputum culture 6 months
of both upper lobes
F, female; M, male.
Figure  1.  Platelet
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